Are There Prognostic Factors Related to Recurrence in Pancreatic Endocrine Tumors?
References (16)
- et al.
Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours
Ann Oncol
(2008) - et al.
Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors
Hum Pathol
(2009) - et al.
Endocrine pancreatic tumors: factors correlated with survival
Ann Oncol
(2005) - et al.
Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival
J Am Coll Surg
(2003) - et al.
Surgical treatment of pancreatic endocrine neoplasms
Am J Surg
(2007) - et al.
The surgical management of MEN-1 pancreatoduodenal neuroendocrine disease
Surgery
(2004) - et al.
Revised classification of neuroendocrine tumours of the lung, pancreas and gut
Virchows Arch
(1995) - et al.
Histological Typing of Endocrine Tumours. World Health Organization International Histological Classification of Tumours
(2000)
Cited by (36)
Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis
2021, Cancer Treatment ReviewsCitation Excerpt :Of these 64 datasets, 56 reported on pancreatic NENs only [9,14,16,19-21,23-31,33-60,62-64,66-70,72-75] (12,418 patients), 3 reported on duodenal NENs (155 patients)[18,54,61] and 5 reported on mixed primary sites including pancreatic, gastroduodenal, gastric and small bowel NENs (1,142 patients) [7,15,32,65,71]. Of the 64 datasets included, 24 reported on grade 1–2 tumours only [9,15,16,21,22,29,32,38,40,45,46,48,49,53,54,57,61,64,65,69-71,74] (4,735 patients) and 40 included grade 1–3 tumours [7,13,14,18,19,21-24,27-32,34,35,37-41,43,45-48,51,54-56,59,60,62-64,66,67,69-71,75] (8,980 patients). Of the 63 included studies, 23 studies included patients with metastatic disease that was resected with curative intent in their analyses.
Pancreatic Neuroendocrine Neoplasms: Does Sex Matter?
2020, Trends in Endocrinology and MetabolismNovel scoring system for recurrence risk classification of surgically resected G1/2 pancreatic neuroendocrine tumors - Retrospective cohort study
2020, International Journal of SurgeryCitation Excerpt :Other than the poor prognosis of patients with pancreatic cancer (approximately 8% for post-diagnosis 5-year survival rate [3]), life expectancy for PanNENs patients seems to be better with 5-year survival rates from 97% for insulinomas to 30% for nonfunctional metastatic tumors [4]. Resection is regarded as the primary approach for localized PanNENs patients [4,5] and disease recurrence ranges from 21% to 42% according to previous studies [6–8]. The World Health Organization (WHO) classified PanNENs into three subgroups based on the proliferation activity of tumor cells and distinguished pancreatic neuroendocrine tumor (PanNET) and pancreatic neuroendocrine carcinoma (PanNEC) in 2010 [9].
Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors
2017, Annals of OncologyCitation Excerpt :The current study addresses this issue to a certain extent by identifying subgroups at higher risk of recurrence: elderly patients with regional stage, higher grade tumors, and those arising in certain primary sites including the pancreas. These findings on association between stage, site, grade and risk of recurrence are in line with prior smaller-scale studies on some NETs [6–10]. Future studies should validate the findings from our study across age groups and primary sites to pave the way for adjuvant trials in these subgroups.
- 1
Riccardo Casadei, MD Dipartimento di Scienze Chirurgiche e Anestesiologiche, Chirurgia Generale-Minni Alma Mater Studiorum, Università di Bologna, Policlinico S. Orsola-Malpighi Via Massarenti n.9, IT-40138 Bologna (Italy) Tel. +39 051 341 541, Fax +39 051 341 483